Article Text

Download PDFPDF

#36419 Effect of COVID-19 in regulation of implantable intrathecal pumps for benign chronic pain management
  1. Dimitrios Peios1,
  2. Athanasia Tsaroucha2,
  3. Christina Ble3,
  4. Periklis Zavridis4 and
  5. Georgios Matis5
  1. 1Functional Neurosurgery, St Luke’s private hospital, Thessaloniki, Greece
  2. 2Pain Department , Aretaieio University Hospital, Athens, Greece
  3. 3Functional Neurosurgery, St Luke’s private hospital, Thessaloniki , Greece
  4. 4Pain Department , Cyprus Pain Clinic, Nicosia, Cyprus
  5. 5Functional Neurosurgery, Cologne University Hospital, Cologne, Germany


Please confirm that an ethics committee approval has been applied for or granted: Not relevant (see information at the bottom of this page)

Application for ESRA Abstract Prizes: I don’t wish to apply for the ESRA Prizes

Background and Aims Implantable intrathecal pain pump is a well established chronic pain management method that has been used successfully for the treatment of benign chronic intractable pain of various etiologies. The regulation of the pumps requires repeating monitoring and refill at specific intervals and occasionally reevaluation and modification of the daily dose that the pump administers. The aim of this study was to evaluate the effect of the Covid-19 pandemic to the treatment of these patients.

Methods A retrospective analysis of the data collected from the outpatient departments concerning management and regulation of patients with implanted intrathecal pump for benign pain management. The data of 35 patients were collected regarding the scheduled refills, ability to access medical services, availability of intrathecal drugs and requests to alter dosage with or without COVID infection.

Results There was no significant alteration to the routine of these patients regarding the scheduled refills and availability of drugs, except one specific type, although these actions were performed under the regulation of each hospital in special designated areas and with full precaution. As far as the effect of infection itself, although many patients experienced some musculoskeletal deterioration, almost all were treated with brief oral pain medication and none received or requested an increase in intrathecal drugs.

Conclusions From our analysis it seems that the patients with implanted intrathecal pain pumps with having the main drug an opioid were not affected in terms of medical services and pump performance from the Covid-19 pandemic.

  • Covid-19
  • pain management
  • neuromodulation
  • intrathecal pump
  • opioids

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.